Data as of Aug 20
| -0.21 / -1.54%|
The 8 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 17.50, with a high estimate of 20.00 and a low estimate of 10.00. The median estimate represents a +30.69% increase from the last price of 13.39.
The current consensus among 9 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.